• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Drug Design, Development and Therapy >A Review on Remdesivir: A Possible Promising Agent for the Treatment of COVID-19
【24h】

A Review on Remdesivir: A Possible Promising Agent for the Treatment of COVID-19

机译：RemdesiviR的综述：用于治疗Covid-19的可能有希望的代理人

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The novel coronavirus 2019 (2019-nCoV), formally named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a novel human infectious coronavirus. The disease caused by SARS-CoV-2 is named COVID-19. Development and manufacturing of specific therapeutics and vaccines to treat COVID-19 are time-consuming processes. At this time, using available conventional therapeutics along with other treatment options may be useful to fight COVID-19. In different clinical trials, efficacy of remdesivir (GS-5734) against Ebola virus has been demonstrated. Moreover, remdesivir may be an effective therapy in vitro and in animal models infected by SARS and MERS coronaviruses. Hence, the drug may be theoretically effective against SARS-CoV-2. Remdesivir is a phosphoramidate prodrug of an adenosine C-nucleoside. By entrance into respiratory epithelial cells in human, the prodrug is metabolized to a nucleoside triphosphate as the active form. The nucleoside analog inhibits the viral RNA-dependent RNA polymerase (RdRp) by competing with the usual counterpart adenosine triphosphate (ATP). The nucleoside analog is incorporated into the generating RNA strand and causes a delayed stop in the viral replication process. Knowledge about the potential efficacy of remdesivir against coronaviruses has been restricted to in vitro studies and animal models. However, information related to COVID-19 is rapidly growing. Several clinical trials are ongoing for the management of COVID-19 using remdesivir. In this study, characteristics of remdesivir and its usage for treatment of COVID-19 are reviewed based on an electronic search using PubMed and Google Scholar.
机译：新型冠状病毒2019（2019-NCOV），正式命名为严重急性呼吸综合征冠状病毒2（SARS-COV-2），是一种新型人类传染性冠状病毒。 SARS-COV-2引起的疾病被命名为Covid-19。治疗Covid-19的特定治疗和疫苗的开发和制造是耗时的过程。此时，使用可用的常规治疗方法以及其他治疗方案可能有助于对抗Covid-19。在不同的临床试验中，已经证明了对埃博拉病毒的雷达尔（GS-5734）的疗效。此外，Remdesivir可以是体外和由SARS和MERS冠状病毒感染的动物模型的有效疗法。因此，该药物可能对SARS-COV-2有效。 Remdesivir是腺苷C-核苷的氨基甲酰胺前药。通过进入人中的呼吸上皮细胞，将前药代谢为核苷三磷酸作为活性形式。核苷类似物通过竞争通常的对应腺苷三磷酸（ATP）抑制病毒RNA依赖性RNA聚合酶（RDRP）。将核苷类似物掺入发电RNA链中，并在病毒复制过程中引起延迟的止挡。关于雷达维尔对冠状病毒的潜在疗效的了解已仅限于体外研究和动物模型。但是，与Covid-19相关的信息迅速增长。使用Remdesivir管理Covid-19的几种临床试验正在进行。在这项研究中，根据使用PubMed和Google Scholar的电子搜索对雷米多维尔的特征及其对Covid-19治疗的用途。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号